NYMC Faculty Publications
Corrigendum: Myelomodulatory Treatments Augment the Therapeutic Benefit of Oncolytic Viroimmunotherapy in Murine Models of Malignant Peripheral Nerve Sheath Tumors
Author Type(s)
Faculty
DOI
10.3389/fimmu.2024.1456897
Journal Title
Frontiers in Immunology
Document Type
Article
Publication Date
1-1-2024
Department
Pediatrics
Keywords
immunotherapy, macrophage targeting, malignant peripheral nerve sheath tumors, oncolytic virotherapy, pexidartinib, T-VEC, trabectedin, tumor microenvironment
Disciplines
Medicine and Health Sciences
Abstract
In the published article, there was an error in the legend for Figure 1 as published. We mistaken referred to the tumor models as xenografts instead of syngeneic models in the sentence: “We first compared different oHSV constructs for their ability to kill MPNST cells and shrink MPNST xenografts.” The corrected legend appears below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Recommended Citation
Paudel, S., Hutzen, B., Miller, K., Garfinkle, E., Chen, C., Wang, P., Glaspell, A., Currier, M., Ringwalt, E., Boon, L., Mardis, E., Cairo, M., Ratner, N., Dodd, R., Cassady, K., & Cripe, T. (2024). Corrigendum: Myelomodulatory Treatments Augment the Therapeutic Benefit of Oncolytic Viroimmunotherapy in Murine Models of Malignant Peripheral Nerve Sheath Tumors. Frontiers in Immunology, 15. https://doi.org/10.3389/fimmu.2024.1456897
